Internal dosimetry and biodistribution of indigenously prepared 177Lu-DOTA-rituximab in lymphoma and other hematological malignancies treated with rituximab.

Autor:	Edamadaka Y; Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe.; Homi Bhabha National Institute., Parghane RV; Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe.; Homi Bhabha National Institute., Sahu S; Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe., Lad S; Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe., Kamaldeep; Homi Bhabha National Institute.; Health Physics Division, Bhabha Atomic Research Centre., Wanage G; Homi Bhabha National Institute.; Health Physics Division, Bhabha Atomic Research Centre., Shanmukhaiah C; Department of Hematology, King Edward Memorial Hospital., Kulkarni V; Department of Hematology, TN Medical College and BYL Nair Hospital, Mumbai, Maharashtra, India., Basu S; Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe.; Homi Bhabha National Institute.
Jazyk:	angličtina
Zdroj:	Nuclear medicine communications [Nucl Med Commun] 2024 Jun 28. Date of Electronic Publication: 2024 Jun 28.
DOI:	10.1097/MNM.0000000000001875
Abstrakt:	Objective: The aim of this study was to evaluate the biodistribution and dosimetry of lutetium-177-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (177Lu-DOTA)-rituximab in CD20+ non-Hodgkin's lymphoma and other hematological malignancies treated with rituximab. Methods: The standard dosimetry protocol was used, with cold rituximab infusion, then a diagnostic activity of 177Lu-DOTA-rituximab. Planar images were acquired at multiple time points. Normal organs and tumor dosimetry were performed by using organ and tumor-specific regions of interest and whole-body counts were obtained serially after pixel matched, background, scatter, and attenuation correction. The mean radiation absorbed doses were obtained from OLINDA/EXM v2.1.1 and ORIGIN software. Results: A total of 22 patients were included in this study. Prolonged blood pool clearance of 177Lu-DOTA-rituximab with long residence time in the blood pool and normal organs were observed. The whole body effective half-life was 104.5 ± 22 h. The mean total body radiation absorbed dose was 0.208 ± 0.03 mGy/MBq and the mean total body effective dose was 0.196 ± 0.05 mGy/MBq of 177Lu-DOTA-rituximab. The mean radiation absorbed doses of 0.613 ± 0.21, 1.68 ± 2, 1.01 ± 0.42, and 0.136 ± 0.02mGy/MBq were seen for the liver, spleen, kidneys, and bone marrow, respectively. Tumor lesion uptake was noticed in two patients with tumor radiation absorbed doses were 0.842 mGy/MBq in one and 9.9 mGy/MBq in the other patient. A strong correlation was obtained between the cumulative activities of radiation-absorbed doses derived from ORIGIN and OLINDA software methods at a significant P value less than 0.001. Conclusion: The results of our study demonstrated favorable biodistribution and dosimetry of indigenously produced 177Lu-DOTA-rituximab in patients with CD20+ lymphoma. These results can be used for future studies of radioimmunotherapy employing 177Lu-DOTA-rituximab. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu